Skip to main
TRAW

Traws Pharma (TRAW) Stock Forecast & Price Target

Traws Pharma (TRAW) Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Traws Pharma is expected to have a positive outlook due to its strong pipeline of product candidates, multiple sources of revenue from collaboration and licensing agreements, and a moderate weighted average cost of capital of 19.0%. However, potential risks include financing, clinical trial, regulatory, delisting, and bankruptcy risks, which may impact the company's financials and market performance. Additionally, success in their pipeline and a larger addressable market for viruses such as COVID, hantavirus, or Ebola could potentially lead to upside opportunities for the company.

Bears say

Traws Pharma is facing potential setbacks in their TXM influenza program as a result of negative reviews from regulators. The FDA has placed a clinical hold on the U.S. IND for TXM, while the MHRA in the UK has expressed concerns about safety and genotoxicity within the clinical package. This could delay the development of TXM and push the lead program toward additional regulatory work or a backup-candidate strategy.

Traws Pharma (TRAW) has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Traws Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Traws Pharma (TRAW) Forecast

Analysts have given Traws Pharma (TRAW) a Hold based on their latest research and market trends.

According to 1 analysts, Traws Pharma (TRAW) has a Hold consensus rating as of Jul 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Traws Pharma (TRAW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.